Incretin-based agents such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) represent a new class of AOMs that were initially used to treat type 2 diabetes mellitus (T2DM) [8]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.